dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Hydrolases & Lipases (type: enzyme)
Target: PLA<sub>2</sub>-G7

Ligand: ABX-1431 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5 pIC50
Reference (Journal): Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders.
Published in: J Med Chem

Ligand: compound 37 [PMID: 29193967] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.849999904632568 pIC50
Reference (Journal): Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
Published in: J Med Chem

Ligand: darapladib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.460000038146973 pIC50
Reference (Journal): Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2).
Published in: J Med Chem

Ligand: darapladib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 10.3100004196167 pIC50
Reference (Journal): Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2).
Published in: J Med Chem

Ligand: darapladib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.960000038146973 pIC50
Reference (Journal): The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.
Published in: Bioorg Med Chem Lett

Ligand: (S)-23 [PMID: 27933945] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.489999771118164 pIC50
Reference (Journal): Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2).
Published in: J Med Chem

Ligand: (S)-23 [PMID: 27933945] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.920000076293945 pIC50
Reference (Journal): Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2).
Published in: J Med Chem

Ligand: rilapladib (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Primary target: yes
Median affinity: 9.640000343322754 pIC50
Reference (Journal): Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Published in: Curr Opin Lipidol
Target family: Hydrolases & Lipases (type: enzyme)
Target: PLD2

Ligand: ADP-ribosylation factor 1 (Peptide)
Interaction type: Activator
Action: Activation
Ligand approved: no
Median affinity:  -

Ligand: compound 69 [PMID: 19136975] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.03000020980835 pIC50
Reference (Journal): Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
Published in: Nat Chem Biol

Ligand: FIPI (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.769999980926514 pIC50
Reference (Journal): Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
Published in: Nat Chem Biol

Ligand: oleic acid (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: no
Median affinity:  -
Reference (Journal): Endogenous phospholipase D2 localizes to the plasma membrane of RBL-2H3 mast cells and can be distinguished from ADP ribosylation factor-stimulated phospholipase D1 activity by its specific sensitivity to oleic acid.
Published in: Biochem J

Ligand: PIP2 (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: no
Median affinity:  -
Reference (Journal): Cloning and initial characterization of a human phospholipase D2 (hPLD2). ADP-ribosylation factor regulates hPLD2.
Published in: J Biol Chem

Ligand: VU0364739 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.7 pIC50
Reference (Journal): Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.
Published in: J Med Chem
Target family: Hydrolases & Lipases (type: enzyme)
Target: sPLA<sub>2</sub>-2A

Ligand: compound 12e [PMID: 18605714] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pIC50
Reference (Journal): Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
Published in: J Med Chem

Ligand: KH064 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.5 pIC50
Reference (Journal): D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity.
Published in: Chembiochem

Ligand: varespladib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI.
Published in: J Pharmacol Exp Ther

Ligand: varespladib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pIC50
Reference (Journal): Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.
Published in: J Med Chem

Ligand: varespladib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.
Published in: J Med Chem
Target family: Hydrolases & Lipases (type: enzyme)
Target: vanin 1

Ligand: example 25 [WO2018228934] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 10 pIC50
Reference (Patent): HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS

Ligand: vanin-1 inhibitor [PMID: 33196323] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.470000267028809 pIC50
Reference (Journal): Pharmacological inhibition of Vanin-1 is not protective in models of acute and chronic kidney disease.
Published in: Am J Physiol Renal Physiol

Ligand: vanin-1 inhibitor [PMID: 33196323] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.819999694824219 pIC50
Reference (Journal): Pharmacological inhibition of Vanin-1 is not protective in models of acute and chronic kidney disease.
Published in: Am J Physiol Renal Physiol
Target family: Hydroxycarboxylic acid receptors (type: gpcr)
Target: HCA<sub>1</sub> receptor

Ligand: 3,5-dihydroxybenzoic acid (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 3.76 pEC50
Reference (Journal): 3,5-Dihydroxybenzoic acid, a specific agonist for hydroxycarboxylic acid 1, inhibits lipolysis in adipocytes.
Published in: J Pharmacol Exp Ther
Target family: Hydroxycarboxylic acid receptors (type: gpcr)
Target: HCA<sub>2</sub> receptor

Ligand: acipimox (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: UK (2003)
Primary target: no
Median affinity:  pEC50
Reference (Journal): Molecular identification of high and low affinity receptors for nicotinic acid.
Published in: J Biol Chem

Ligand: acifran (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G.
Published in: J Biol Chem

Ligand: acifran (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
Published in: J Med Chem

Ligand: acifran (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74.
Published in: Biochem Biophys Res Commun

Ligand: acifran (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Molecular identification of high and low affinity receptors for nicotinic acid.
Published in: J Biol Chem

Ligand: 5-methyl nicotinic acid (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5.1 pEC50
Reference (Journal): Molecular identification of high and low affinity receptors for nicotinic acid.
Published in: J Biol Chem

Ligand: 5-butyl-1H-pyrazole-3-carboxylic acid (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity: 7.1 pKi
Reference (Journal): Pyrazole derivatives as partial agonists for the nicotinic acid receptor.
Published in: J Med Chem

Ligand: (+)-5-(5-bromothiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.3 pEC50
Reference (Journal): Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
Published in: J Med Chem

Ligand: (+)-5-(5-bromothiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.3 pEC50
Reference (Journal): (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G.
Published in: J Biol Chem

Ligand: 3-pyridine-acetic acid (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5.3 pEC50
Reference (Journal): Molecular identification of high and low affinity receptors for nicotinic acid.
Published in: J Biol Chem
Target family: Hypoxia-inducible factors (type: other_protein)
Target: endothelial PAS domain protein 1

Ligand: PT2385 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pKd
Reference (Journal): A Small-Molecule Antagonist of HIF2&#x3b1; Is Efficacious in Preclinical Models of Renal Cell Carcinoma.
Published in: Cancer Res

Ligand: belzutifan (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: yes
Approval source: FDA (2021)
Primary target: no
Median affinity: 8.050000190734863 pIC50
Reference (Journal): 3-[(1<i>S</i>,2<i>S</i>,3<i>R</i>)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma.
Published in: J Med Chem
Target family: IKK family (type: enzyme)
Target: component of inhibitor of nuclear factor kappa B kinase complex

Ligand: compound 47 [PMID: 28737909] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.190000057220459 pKi
Reference (Journal): Inhibitory Kappa B Kinase α (IKKα) Inhibitors That Recapitulate Their Selectivity in Cells against Isoform-Related Biomarkers.
Published in: J Med Chem

Ligand: BMS-345541 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Primary target: no
Median affinity: 5.400000095367432 pIC50
Reference (Journal): BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice.
Published in: J Biol Chem

Ligand: BAY 61-3606 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.349999904632568 pKi
Reference (Journal): Inhibition of IKKα by BAY61-3606 Reveals IKKα-Dependent Histone H3 Phosphorylation in Human Cytomegalovirus Infected Cells.
Published in: PLoS ONE
Target family: IKK family (type: enzyme)
Target: inhibitor of nuclear factor kappa B kinase subunit epsilon

Ligand: SR8185 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.520000457763672 pIC50
Reference (Journal): Selective TBK1/IKKi dual inhibitors with anticancer potency.
Published in: Int J Cancer

Ligand: MRT67307 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.800000190734863 pIC50
Reference (Journal): Novel cross-talk within the IKK family controls innate immunity.
Published in: Biochem J

Ligand: MPI-0485520 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.520000457763672 pIC50
Reference (Patent): Pyrimidine compounds as inhibitors of protein kinases ikk epsilon and/or tbk-1, processes for their preparation, and pharmaceutical compositions containing them

Ligand: GSK8612 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.099999904632568 pKd
Reference (Journal): Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
Published in: ACS Med Chem Lett

Ligand: compound II [PMID: 21329883] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.230000019073486 pIC50
Reference (Journal): TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation.
Published in: Mol Cell

Ligand: compound 17d [PMID: 23099093] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.519999980926514 pIC50
Reference (Journal): Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKε kinases.
Published in: Bioorg Med Chem Lett

Ligand: BX-795 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.389999866485596 pIC50
Reference (Journal): Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation.
Published in: J Biol Chem
Target family: IKK family (type: enzyme)
Target: TANK binding kinase 1

Ligand: compound 17d [PMID: 23099093] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.220000267028809 pIC50
Reference (Journal): Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKε kinases.
Published in: Bioorg Med Chem Lett
Target family: IKK family (type: enzyme)
Target: inhibitor of nuclear factor kappa B kinase subunit epsilon

Ligand: BAY-985 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.
Published in: J Med Chem

Ligand: amlexanox (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996)
Primary target: no
Median affinity:  pIC50
Reference (Journal): An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice.
Published in: Nat Med
Target family: IKK family (type: enzyme)
Target: component of inhibitor of nuclear factor kappa B kinase complex

Ligand: PHA-408 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.849999904632568 pIC50
Reference (Journal): A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models.
Published in: J Pharmacol Exp Ther
Target family: IL-10 receptor family (type: catalytic_receptor)
Target: Interleukin-22&alpha;1/20&beta; heteromer

Ligand: IL-24 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-10 receptor family (type: catalytic_receptor)
Target: Interferon-&lambda; receptor 1

Ligand: IFN-λ2 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IFN-λ1 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IFN-λ3 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-10 receptor family (type: catalytic_receptor)
Target: Interleukin-22&alpha;1/20&beta; heteromer

Ligand: IL-20 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-10 receptor family (type: catalytic_receptor)
Target: Interleukin-22&alpha;1/10&beta; heteromer

Ligand: IL-22 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 11.460000038146973 pEC50
Reference (Journal): Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases.
Published in: Biochem Pharmacol

Ligand: efmarodocokin alfa (Antibody)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.920000076293945 pEC50
Reference (Journal): Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases.
Published in: Biochem Pharmacol
Target family: IL-10 receptor family (type: catalytic_receptor)
Target: Interleukin-20 receptor

Ligand: IL-24 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IL-20 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IL-19 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-10 receptor family (type: catalytic_receptor)
Target: Interleukin 10 receptor, &alpha; subunit

Ligand: IL-10 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Interleukin-10: new perspectives on an old cytokine.
Published in: Immunol Rev
Target family: IL-10 receptor family (type: catalytic_receptor)
Target: Interleukin-10 receptor

Ligand: IL-10 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-12 receptor family (type: catalytic_receptor)
Target: Interleukin-12 receptor

Ligand: IL-12 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-12 receptor family (type: catalytic_receptor)
Target: Interleukin-23 receptor

Ligand: IL-23 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-17 receptor family (type: catalytic_receptor)
Target: Interleukin-17 receptor

Ligand: IL-17F (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IL-17A/IL-17F (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-17 receptor family (type: catalytic_receptor)
Target: Interleukin 17 receptor A

Ligand: brodalumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: Japan (2016), FDA (2017), EMA (2017)
Primary target: yes
Median affinity: 9.15999984741211 pKd
Reference (Patent): Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto.
Target family: IL-17 receptor family (type: catalytic_receptor)
Target: Interleukin-25 receptor

Ligand: IL-17B (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-17 receptor family (type: catalytic_receptor)
Target: Interleukin-17 receptor

Ligand: IL-17A (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-17 receptor family (type: catalytic_receptor)
Target: Interleukin-25 receptor

Ligand: IL-25 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-17 receptor family (type: catalytic_receptor)
Target: Interleukin-17C receptor

Ligand: IL-17C (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Interleukin-13 receptor subunit &alpha;1

Ligand: eblasakimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 10.569999694824219 pKd
Reference (Patent): Antibodies against g-csfr and uses thereof
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Interleukin-2 receptor subunit &alpha;

Ligand: basiliximab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (1998), EMA (1998)
Primary target: no
Median affinity:  -

Ligand: daclizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA FDA (1997), EMA (1999)
Primary target: yes
Median affinity: 8 pKd
Reference (Patent): Genetic engineering; complementarity zones.
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Interleukin-2 receptor subunit &beta;

Ligand: bempegaldesleukin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.75 pKd
Reference (Journal): Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
Published in: PLoS ONE
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Interleukin-4 receptor subunit &alpha;

Ligand: dupilumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: EMA & FDA (2017)
Primary target: yes
Median affinity: 11.0600004196167 pIC50
Reference (Patent): Cytokine specific immunoglobulin for use in diagnosis, prevention and treatment ,of cell proliferative, inflammatory, allergic, respiratory, autoimmune and arthritic disorders.
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Interleukin-4 receptor type I

Ligand: IL-4 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Interleukin-4 receptor type II

Ligand: IL-13 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IL-4 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: IL-2 receptor family (type: catalytic_receptor)
Target: Interleukin-7 receptor

Ligand: IL-7 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -